ERBB2 and breast cancer: In patients with HR+/HER2– and lymph node-negative breast cancer, the Oncotype recurrence score (Oncotype DX Breast Recurrence Score, RS) assay has been shown to predict the risk of breast cancer recurrence and of gaining benefit from adjuvant chemotherapy (9–13).